Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington’s Patients.

Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington’s Patients.

Publication date: Jan 07, 2020

Cellavita-HD is a stem-cell therapy for Huntington’s Disease. Open label, single treatment, extension study for long-term safety and efficacy evaluation of Cellavita-HD intravenous administration in Huntington’s disease patients who participated of ADORE-DH trial.

Concepts Keywords
BMI Cell therapy
Body Mass Index PBT2
Bovine Clinical trial protocols
Clinical Laboratory Clinical trial
Clinical Trial Clinical pharmacology
Cognition Design of experiments
Cognitive Pharmaceutical industry
Comorbidity Clinical research
Contraceptive Medical research
Cycle 10 Health
Dose Response Stem cell therapy
Huntington Contraceptive method
Hypersensitivity Hypersensitivity
Immunosuppressive Drugs Clinical trial protocols
Incidence
Intravenous
Lactating
Malignant
Neoplasia
Neurological
Physician
Protocol
Stem Cell Therapy
Suicide

Semantics

Type Source Name
pathway KEGG Huntington disease
disease MESH Huntington Disease
disease MESH hypersensitivity
disease MESH comorbidity
disease MESH neoplasia

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *